What peptide products does Thinheal supply?

Thinheal supplies generic peptide APIs, therapeutic peptides including GLP-1 and GLP-2 analogues, other gastrointestinal peptides, other therapeutic peptide APIs and cosmetic peptides, plus custom peptide R&D and CDMO manufacturing.

Does Thinheal offer custom peptide synthesis and CDMO services?

Yes. The CDMO business covers project-based contract research and development, contract manufacturing and commercial supply, from route design and process optimization to scale-up of peptide APIs and support toward formulations.

What production capacity does Thinheal have?

Thinheal operates an R&D center and a production base. Total capacity for chemically synthesized peptides has reached a multi-ton level, placing the company among the leading peptide producers in its segment.

Which quality documents can buyers request?

Buyers can request batch-specific Certificates of Analysis with HPLC purity and mass spectrometry identity data, and discuss additional documentation such as specifications, stability information and regulatory support files with the sales team for each project.

How can international buyers get the latest product catalog?

Use the Request a Catalog page or contact the regional desk for the USA and Europe, Russia and CIS, Asia, or the Middle East and East Asia by email, phone or WhatsApp.

Custom Setmelanotide CAS: 920014-72-8 Manufacturers, Quotes

1 / 1

Custom Setmelanotide CAS: 920014-72-8 Manufacturers, Quotes

Setmelanotide is a first-in-class melanocortin-4 receptor (MC4R) agonist used to treat a rare genetic obesity disorder caused by a specific gene defect. It helps restore energy balance and weight control in patients by activating the MC4R pathway in the hypothalamus (which plays a central role in regulating hunger, energy expenditure, and weight).

Key features:

Mechanism of action: Selectively activates MC4R, mimicking the effects of the natural hormone α-melanocyte-stimulating hormone (α-MSH), reducing hunger and increasing satiety.

Administration method: Subcutaneous injection once daily.

Primary target diseases:

POMC deficiency obesity (including PCSK1 deficiency)

LEPR deficiency obesity

BBSome gene-related obesity (such as Bardet-Biedl syndrome)

Send Inquiry

Product Description

Mechanism of Action

Selectively activates MC4R, mimicking the effects of the natural hormone α-melanocyte-stimulating hormone (α-MSH), reducing hunger and increasing satiety.

Administration Method

Subcutaneous injection once daily.

Primary Target Diseases

POMC deficiency obesity (including PCSK1 deficiency)
LEPR deficiency obesity
BBSome gene-related obesity (such as Bardet-Biedl syndrome)

Therapeutic Areas

Setmelanotide primarily focuses on rare genetic obesity disorders, specifically including:

Monogenic Obesity

POMC/PCSK1 deficiency: Patients have insufficient activation of the MC4R pathway due to mutations in the POMC or PCSK1 genes, which manifests as early severe obesity, adrenal insufficiency, etc.

LEPR deficiency: A defect in the leptin receptor leads to the failure of the leptin signaling pathway, causing intense hunger and uncontrolled weight gain.

Syndrome-Related Obesity

Bardet-Biedl syndrome (BBS): A multi-system ciliary disorder that is often accompanied by severe obesity, retinopathy, polydactyly, etc.

Alström syndrome (clinical trial phase): A multisystemic disease similar to BBS, accompanied by early obesity and metabolic abnormalities.

Other MC4R Pathway-Related Obesity

Further research is underway on other gene variants involving the MC4R pathway (such as SH2B1, NCOA1, etc.).

Outlook & Development

1. Current Market and Clinical Standing

Approved indications: FDA and EMA approved for use in obese patients aged 6 years and older with POMC/PCSK1/LEPR deficiency or BBS.

Efficacy data: In pivotal clinical trials, most patients experienced significant weight loss (≥10%) and substantial improvement in hunger scores.

Commercialization progress: As a rare disease treatment, it is priced high, but accessibility is gradually being expanded through health insurance negotiations.

2. Expansion of the R&D Pipeline

Generalized MC4R pathway obesity: The TEMPO registry study explores the therapeutic effects on patients with other MC4R pathway gene variants, and may expand the scope of indications in the future.

Exploring combination therapies: When used in combination with metabolic drugs such as GLP-1 receptor agonists, it may be effective for a wider range of obese individuals (such as those with general obesity and impaired MC4R function).

3. Challenges and Opportunities

The patient population is extremely small: The market size is limited by the indication for rare diseases, and long-term real-world data is needed to verify the efficacy and safety.

Administration method: Daily injection may affect compliance, and oral formulation development has not yet made a breakthrough.

Competitive landscape: GLP-1 drugs (such as semaglutide) dominate the field of general obesity, and setmelanotide needs to consolidate its irreplaceable position in precision medicine.

A paradigm of precision medicine: As the first obesity therapy targeting a specific genetic defect, it provides a paradigm for gene-guided therapy.

Expanded indications: If efficacy is demonstrated in more MC4R pathway-related obesity cases, the patient population may be expanded.

Pediatric market: Growing demand for early intervention for rare childhood obesity.

4. Market Prospects

In the short term: Solidify its position as the standard treatment in the field of rare hereditary obesity, with penetration increasing as genetic testing becomes more widespread.

Long-term: If the market can be successfully expanded to a wider range of MC4R-related obesity subtypes, or if combination therapies can be developed, the market potential could be further increased. Meanwhile, in-depth research into the MC4R pathway may lead to a new generation of oral or long-acting formulations.

Conclusion

In summary, Setmelanotide is a breakthrough therapy in the field of rare genetic obesity, filling a clinical gap by precisely targeting the MC4R pathway. Its future value will depend on the expansion of its indications, the development of combination therapies, and its deeper positioning in precision obesity medicine.

Frequently Asked Questions (FAQ)

Q: What is the primary function of Setmelanotide?

Setmelanotide is an MC4R agonist that re-establishes energy balance and controls hunger in individuals suffering from severe, rare genetic obesity conditions.

Q: How is Setmelanotide administered?

It is administered through a daily subcutaneous injection.

Q: Who is eligible for Setmelanotide treatment?

It is approved by the FDA and EMA for adult and pediatric patients aged 6 years and older with verified genetic defects including POMC, PCSK1, or LEPR deficiency, as well as Bardet-Biedl syndrome (BBS).

Q: How does Setmelanotide differ from common weight-loss medications like GLP-1 receptor agonists?

Unlike broad-spectrum medications targeting general obesity, Setmelanotide is a precision medicine approach specifically formulated to treat obesity arising directly from genetic defects in the MC4R pathway.

Q: What are the ongoing research prospects for Setmelanotide?

Research is expanding into other MC4R-related genetic variants, the clinical evaluation of combination therapies with metabolic agents, and future developments toward oral or long-acting formulations.